BrainScope's markets include the military, emergency departments, urgent care clinics, and both collegiate and professional-level sports programs.
It uses electroencephalographic data, artificial intelligence, machine learning technology, cognitive performance and clinical assessments to help identify mTBIs.
[2][3] BrainScope also uses neurocognitive tests (Procedural Reaction Time & Match to Sample), which are performed by the patient on the device, as well as using a library of digitized concussion assessments.
An independent validation trial conducted using BrainScope determined that the device's sensitivity to "≥1 mL of blood was ... 98.6%" and that its accurate CT-scan predictions can lead to a "potential reduction in the number of head C.T.
The Concussion Index algorithm is FDA cleared for use on patients 13–25 years of age with a GSC score of 15 and can be used with 72 hours of acute injury, for baseline and throughout recovery.